Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Madrigal Pharmaceuticals Q1 2024 GAAP EPS $(7.38) Misses $(6.17) Estimate

Author: Benzinga Newsdesk | May 07, 2024 07:21am
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(7.38) per share which missed the analyst consensus estimate of $(6.17) by 19.61 percent.

Posted In: MDGL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist